E-LIB Suche - Ergebnisse für: Gipe, Daniel

1

ANGPTL3 Inhibition With Evinacumab Results in Faster Cleara..:

Reeskamp, Laurens F. ; Millar, John S. ; Wu, Liya...
Arteriosclerosis, Thrombosis, and Vascular Biology. 41 (2021) 5 - p. 1753-1759 , 2021

Link: https://doi.org/10.1161/..

2

Safety, Tolerability, and Pharmacokinetics of Evinacumab, a..:

Ali, Shazia ; Harada-Shiba, Mariko ; Gipe, Daniel...
Journal of Clinical Lipidology. 14 (2020) 4 - p. 581 , 2020

Link: https://doi.org/10.1016/..

3

The Efficacy and Safety of Evinacumab in Homozygous Familia..:

Rosenson, Robert ; Raal, Frederick ; Reeskamp, Laurens...
Journal of Clinical Lipidology. 14 (2020) 4 - p. 552 , 2020

Link: https://doi.org/10.1016/..

4

A randomized study investigating the safety, tolerability, ..:

Harada-Shiba, Mariko ; Ali, Shazia ; Gipe, Daniel A....
Atherosclerosis. 314 (2020) - p. 33-40 , 2020

Link: https://doi.org/10.1016/..

5

Safety and Efficacy of Evinacumab, A Monoclonal Antibody to..:

Gaudet, Daniel ; Gipe, Daniel ; Hovingh, Kees...
Journal of Clinical Lipidology. 11 (2017) 3 - p. 837-838 , 2017

Link: https://doi.org/10.1016/..

6

Efficacy and safety of the proprotein convertase subtilisin..:

Kastelein, John J.P. ; Hovingh, G. Kees ; Langslet, Gisle...
Journal of Clinical Lipidology. 11 (2017) 1 - p. 195-203.e4 , 2017

Link: https://doi.org/10.1016/..

7

Safety and efficacy of evinacumab, a monoclonal antibody to..:

Gaudet, Daniel ; Gipe, Daniel ; Hovingh, Kees...
Atherosclerosis. 263 (2017) - p. e9 , 2017

Link: https://doi.org/10.1016/..

8

Open-label therapy with alirocumab in patients with heteroz..:

Dufour, Robert ; Bergeron, Jean ; Gaudet, Daniel...
International Journal of Cardiology. 228 (2017) - p. 754-760 , 2017

Link: https://doi.org/10.1016/..

9

Safety and efficacy of evinacumab, a monoclonal antibody to..:

Gaudet, Daniel ; Gipe, Daniel A. ; Pordy, Robert...
Journal of Clinical Lipidology. 10 (2016) 3 - p. 715 , 2016

Link: https://doi.org/10.1016/..

10

ODYSSEY FH I and FH II: 78 week results with alirocumab tre..:

Kastelein, John J.P. ; Ginsberg, Henry N. ; Langslet, Gisle...
European Heart Journal. , 2015

Link: https://doi.org/10.1093/..

11

Efficacy and safety of alirocumab vs ezetimibe in statin-in..:

Moriarty, Patrick M. ; Thompson, Paul D. ; Cannon, Christopher P....
Journal of Clinical Lipidology. 9 (2015) 6 - p. 758-769 , 2015

Link: https://doi.org/10.1016/..

12

Efficacy and Safety of Alirocumab in Patients with Heterozy..:

Kastelein, John J. P. ; Robinson, Jennifer G. ; Farnier, Michel...
Cardiovascular Drugs and Therapy. 28 (2014) 3 - p. 281-289 , 2014

Link: https://doi.org/10.1007/..

13

Effect of Alirocumab, a Monoclonal Proprotein Convertase Su..:

Gaudet, Daniel ; Kereiakes, Dean J. ; McKenney, James M....
The American Journal of Cardiology. 114 (2014) 5 - p. 711-715 , 2014

Link: https://doi.org/10.1016/..

14

Efficacy and safety of alirocumab, a monoclonal antibody to..:

Moriarty, Patrick M. ; Jacobson, Terry A. ; Bruckert, Eric...
Journal of Clinical Lipidology. 8 (2014) 6 - p. 554-561 , 2014

Link: https://doi.org/10.1016/..

15

Serum PCSK9 Levels Distinguish Individuals Who Do Not Respo..:

Taylor, Beth A. ; Panza, Gregory ; Pescatello, Linda S....
Journal of Lipids. 2014 (2014) - p. 1-3 , 2014

Link: https://doi.org/10.1155/..